{"id":6506,"date":"2026-02-14T18:38:29","date_gmt":"2026-02-14T18:38:29","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/6506\/"},"modified":"2026-02-14T18:38:29","modified_gmt":"2026-02-14T18:38:29","slug":"roche-signs-agreement-to-acquire-89bio-in-2-4bn-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/6506\/","title":{"rendered":"Roche signs agreement to acquire 89bio in $2.4bn deal"},"content":{"rendered":"

\"\"\/<\/p>\n

The boards of directors of both Roche and 89bio unanimously approved the transaction. Credit: F. Hoffmann-La Roche Ltd.<\/p>\n

Roche has signed a definitive merger agreement for the acquisition of clinical-stage biopharmaceutical company 89bio, for a total equity value of around $2.4bn.<\/p>\n

Under the deal, Roche will initiate a tender offer to purchase all outstanding shares of 89bio common stock at $14.50 per share in cash.<\/p>\n

\"\"\/ Discover B2B Marketing That Performs <\/p>\n

\n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n


\n\t\t\t\t\t\t\tFind out more <\/a><\/p>\n

This will also include a non-tradeable contingent value right (CVR) that could yield payments of up to $6 per share based on specific milestones.<\/p>\n

The potential total deal value represents up to $3.5bn.<\/p>\n

The offer represents a premium of approximately 52% over 89bio\u2019s 60-day volume-weighted average price as of 17 September 2025.<\/p>\n

The boards of directors of both Roche and 89bio unanimously approved the transaction.<\/p>\n

The deal is anticipated to close in the fourth quarter (Q4) of 2025, subject to customary closing conditions, including the tender of a majority of 89bio\u2019s shares and regulatory approvals.<\/p>\n

Upon closing, 89bio\u2019s current employees will be transitioned to Roche\u2019s pharmaceuticals division.<\/p>\n

Roche Group CEO Thomas Schinecker said: \u201cThis acquisition further strengthens our portfolio in cardiovascular, renal, and metabolic diseases and offers opportunities to explore combinations with existing programmes in our pipeline.<\/p>\n

\u201cWe are highly encouraged by pegozafermin\u2019s potential to become a transformative treatment option in MASH, one of the most prevalent comorbidities of obesity, and to meet diverse patient needs associated with this complex disease.\u00a0<\/p>\n

\u201cWith its combined anti-fibrotic and anti-inflammatory mechanism, pegozafermin could potentially offer best-in-disease efficacy for all moderate to severe MASH patients.\u201d<\/p>\n

The acquisition includes 89bio\u2019s lead product, pegozafermin, a fibroblast growth factor 21 (FGF21) analogue with glycoPEGylated technology.<\/p>\n

Pegozafermin is currently in late-stage trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis.<\/p>\n

Last year, the European Medicines Agency (EMA) granted priority medicines (PRIME<\/a>) status to pegozafermin.<\/p>\n

The CVR entitles 89bio shareholders to contingent cash payments based on the achievement of certain commercial milestones related to pegozafermin.\u00a0<\/p>\n

Citi served as financial adviser while Sidley Austin served as legal adviser to Roche on this transaction.<\/p>\n

Moelis & Company and Centerview Partners served as financial advisers while Gibson, Dunn & Crutcher served as legal adviser to 89bio.\u00a0<\/p>\n

\"Email<\/p>\n

\n Sign up for our daily news round-up!
\n Give your business an edge with our leading industry insights.\n <\/p>\n","protected":false},"excerpt":{"rendered":"The boards of directors of both Roche and 89bio unanimously approved the transaction. Credit: F. Hoffmann-La Roche Ltd.…\n","protected":false},"author":2,"featured_media":6507,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[5366,134],"class_list":{"0":"post-6506","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-deal","9":"tag-roche"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/6506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=6506"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/6506\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/6507"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=6506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=6506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=6506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}